PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
NEW YORK, Sept. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01622980/PharmaPoint-Non-Small-Cell-Lung-Cancer---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
Summary
The Indian NSCLC market has been especially difficult for drug companies to penetrate, and the market revolves almost exclusively around generics. The market is dominated by generic chemotherapies including pemetrexed (Alimta) as well as the generic targeted therapies erlotinib (Tarceva) and gefitinib (Iressa).
Scope
- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in India from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting India NSCLC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in India.1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 102.3 Upcoming Related Reports 123 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology and Histology 133.1.3 NSCLC Biomarkers 143.1.4 Quality of Life 153.2 Symptoms 164 Disease Management 184.1 Treatment Overview 184.1.1 Diagnosis 194.1.2 Clinical Staging 204.1.3 Screening and Early Detection 224.1.4 Localized Procedures and Therapies 234.1.5 Systemic Chemotherapy 244.1.6 Targeted Therapy 254.2 India 274.2.1 Diagnosis 274.2.2 Clinical Practice 285 Competitive Assessment 305.1 Overview 305.2 Strategic Competitor Assessment 315.3 Product Profiles – Major Brands, Chemotherapies 335.3.1 Alimta (pemetrexed disodium) 335.4 Product Profiles – Major Brands, Targeted Therapies 375.4.1 Iressa (gefitinib) 375.4.2 Tarceva (erlotinib hydrochloride) 425.4.3 Xalkori (crizotinib) 485.4.4 Avastin (bevacizumab) 526 Opportunity and Unmet Need 566.1 Overview 566.2 Improved Overall Survival and Less Toxicity 576.3 Treatments for Patients with Acquired TKI Resistance 586.4 Better Treatment Options for Squamous Patients 596.5 Preventing Relapse or Recurrence 596.6 More Efficacious Second-Line Therapies 606.7 Increased Availability of Mutation Testing 606.8 More Cost-Effective Therapies 616.9 Unmet Needs Gap Analysis 627 Pipeline Assessment 667.1 Overview 667.2 Promising Drugs in Clinical Development 667.2.1 nintedanib (BIBF1120) 707.2.2 Gilotrif (afatinib) 747.2.3 dacomitinib (PF-00299804) 807.2.4 LDK378 848 Market Outlook 908.1 India 908.1.1 Forecast 908.1.2 Key Events 948.1.3 Drivers and Barriers 949 Appendix 969.1 Bibliography 969.2 Abbreviations 1089.3 Methodology 1129.4 Forecasting Methodology 1129.4.1 Number of NSCLC Patients Currently Seeking Treatment 1129.4.2 Percent Drug-treated Patients 1139.4.3 Drugs Included in Each Therapeutic Class 1139.4.4 Launch and Patent Expiry Dates 1149.4.5 General Pricing Assumptions 1149.4.6 Individual Drug Assumptions 1179.4.7 Generic Erosion 1219.4.8 Pricing of Pipeline Agents 1229.5 Physicians and Specialists Included in This Study 1249.6 Survey of Prescribing Physicians 1269.7 About the Authors 1279.7.1 Authors 1279.7.2 Epidemiologists 1289.7.3 Global Head of Healthcare 1299.8 About GlobalData 1309.9 Disclaimer 130
1.1 List of Tables
Table 2: Treatment Guidelines for NSCLC 19
Table 3: Stage Definitions for NSCLC 21
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC 27
Table 5: Leading Treatments for NSCLC 33
Table 6: Product Profile – Alimta (pemetrexed disodium) 35
Table 7: Alimta SWOT Analysis, 2013 37
Table 8: Product Profile – Iressa (gefitinib) 39
Table 9: Iressa SWOT Analysis, 2013 42
Table 10: Product Profile – Tarceva (erlotinib hydrochloride) 44
Table 11: Tarceva SWOT Analysis, 2013 47
Table 12: Product Profile – Xalkori (crizotinib) 49
Table 13: Xalkori SWOT Analysis, 2013 52
Table 14: Product Profile – Avastin (bevacizumab) 53
Table 15: Avastin SWOT Analysis, 2013 55
Table 16: Overall Unmet Needs – Current Level of Attainment 57
Table 17: Clinical Unmet Needs – Gap Analysis, 2013 63
Table 18: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013 67
Table 19: NSCLC – Phase III Pipeline, 2013 68
Table 20: NSCLC – Advantages and Disadvantages of Therapeutic Classes 69
Table 21: Product Profile – nintedanib (BIBF-1120) 70
Table 22: nintedanib SWOT Analysis, 2013 74
Table 23: Product Profile – Gilotrif (afatinib) 75
Table 24: Gilotrif SWOT Analysis, 2013 79
Table 25: Product Profile – dacomitinib (PF-00299804) 80
Table 26: dacomitinib SWOT Analysis, 2013 84
Table 27: Product Profile – LDK378 85
Table 28: LDK378 SWOT Analysis, 2013 89
Table 29: Sales Forecasts ($m) for NSCLC in India, 2012-2022 92
Table 30: Key Events Impacting Sales for NSCLC in India, 2012–2022 94
Table 31: NSCLC Market in India – Drivers and Barriers, 2012–2022 94
Table 32: Five Year Prevalence 113
Table 33: Key Launch Dates 114
Table 34: Physicians Surveyed by Country 126
1.2 List of Figures
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022 69Figure 2: Sales for NSCLC in India by Drug, 2012–2022 93
To order this report: PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022 http://www.reportlinker.com/p01622980/PharmaPoint-Non-Small-Cell-Lung-Cancer---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article